Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 100.5 USD -1.52% Market Closed
Market Cap: 6.1B USD

Jazz Pharmaceuticals PLC
Investor Relations

In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets.

Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.

Show more
Loading

Earnings Calls

2024 Q3
Oct 24, 2024
Show Transcript
Previous
Next
Bankinter shows strong growth with improved margins and focused risk management.
2024 Q3
Oct 24, 2024

Bankinter reported solid third-quarter results, with a 5% growth in loans and retail deposits, while off-balance sheet products surged by 23%. The bank achieved a 7% increase in total operating income to €2,151 million, driven by a 5.5% rise in net interest income and a remarkable 14% boost in fees. Profit before taxes rose 8% year-on-year to €1,083 million. Furthermore, the bank maintained a comfortable NPL ratio of 2.2% and a strong CET1 ratio of 12.56%. Looking ahead, expectations for 2025 include continued revenue growth despite potential interest rate declines, with a net interest income target of mid-single digits.

Show Full Analysis

Management

Mr. Bruce C. Cozadd
Co-Founder, Chairman & CEO
No Bio Available
Ms. Renee D. Gala
President & COO
No Bio Available
Ms. Patricia Carr
Senior VP & Chief Accounting Officer
No Bio Available
Ms. Neena M. Patil J.D.
Executive VP & Chief Legal Officer
No Bio Available
Dr. Robert Iannone M.D.
Executive VP, Chief Medical Officer and Global Head of Research & Development
No Bio Available
Mr. Philip L. Johnson
Executive VP & CFO
No Bio Available
Ms. Andrea N. Flynn Ph.D.
VP & Head of Investor Relations
No Bio Available
Ms. Heidi Manna
Executive VP & Chief People Officer
No Bio Available
Dr. Jed Black M.D.
Senior Vice President of Sleep & CNS Medicine
No Bio Available
Ms. Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer
No Bio Available

Contacts

Address
DUBLIN
DUBLIN
Fifth Fl, Waterloo Exchange, Waterloo Road
Contacts
+35316347800.0
www.jazzpharma.com